Protalix is a publicly traded biotechnology company (NYSE Amex: PLX), that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.



PRESS ROOM
10/15/09 Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO™ for the Treatment of Gaucher Disease
09/22/09 Protalix Reports Preclinical Data on Anti-TNF Follow-on Biologic Arthritis Drug
09/14/09 Protalix Completes Pivotal Phase III Trial for prGCD for the Treatment of Gaucher Disease
09/08/09 FDA Grants Protalix Orphan Drug Designation for prGCD
08/25/09 Protalix Receives FDA Fast Track Designation for prGCD
08/17/09 U.S. Food and Drug Administration Approves Protalix's Treatment Protocol for prGCD
08/06/09 Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
07/14/09 Protalix Holds Pre-NDA Meeting with FDA for prGCD
07/06/09 Protalix Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD in Patients with Gaucher Disease Allowing Expanded Access to prGCD
PROTALIX BIOTHERAPEUTICS

2 Snunit St., Science Park,
POB 455, Carmiel 20100, Israel.

T:   +972-4-9028100
F:   +972-4-988-9489
E:   
      
© 2007 Protalix Biotherapeutics. All Rights Reserved.